Biotech | March 11, 2022
Emmes acquires Casimir, its fourth major acquisition
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
As the world celebrates World Glaucoma Week (March 7-13th), Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals, an authority on eye diseases spoke to Thomas C Thottathil, Editor, indianpharmapost.com, on the seriousness of Glaucoma
The RI investment comes on the back of three other recently completed transactions in Malaysia and Singapore in the last two months
It has blended 36 important ingredients for a woman’s health, which has a mix of natural extracts, amino acids, multivitamins and minerals
The Gujarat Biotechnology policy released last month has made radical changes to position the state as a biotechnology hub. It already has a thriving ecosystem of pharma companies and varied suppliers
It is also setting up laboratories in West Bengal, Assam, Bihar, Jharkhand and Orissa to comprehensively cater to the East India region
A total of 21 applicants have been approved for 49 products, with the potential to utilize an incentive amount of Rs. 2541 crore
Subscribe To Our Newsletter & Stay Updated
